Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Avacta Group
Avacta Group
Activities:
Research & Development
Analysis
Pharmaceutical
X
LinkedIn
Trending Articles
Innovation in generics: increased efficiency through peptide API synthesis expertise
Leading Swiss pharmaceutical company Bachem explains the benefits of converging LPPS in the manufacturing of gonadotropin-releasing hormone (GnRH) analogues
COVID-19 still a significant risk for the immunocompromised, study finds
AstraZeneca's INFORM study highlights the persistent danger of COVID-19 for the immunocompromised despite the vaccination scheme
US court lifts modified consent decree on Xellia’s Cleveland facility
The Modified Consent Decree imposed on Xellia's Cleveland facility in 2016 has been vacated, receiving a VAI
Lonza's AI-enabled small molecule development tool launches
The company's AI-enabled Route Scouting Service will optimise synthetic route identification when identifying novel APIs
Autoscribe Informatics’ new Australia office supports business growth
The company's move to West Lakes Adelaide expands its ability to service the Asia Pacific region in digitalising laboratory information
Upcoming event
ASGCT Annual Meeting 2024
7-11 May, 2024 | Meeting | Portland, OR
See all
Related Content
Research & Development
Avacta achieves milestone in AffyXell joint venture
The second milestone will result in an increase in Avacta’s shareholding in AffyXell, which currently stands at 19%
Research & Development
AffyXell expands partnership with GenScript ProBio
As part of the strategic alliance, GenScript has committed to take an equity position in AffyXell at a future funding round
Finance
Avacta appoints Non-Executive Director to board
Christina Coughlin previously served as CMO to Rubius Therapeutics, where she led the clinical development, translational medicine and regulatory efforts for the company
Analysis
Avacta provides update on its antigen test for Omicron
The company has taken the decision to pause sales of the AffiDX antigen test while it replaces the antibody in the product to ensure its performance with the Omicron variant matches that of the previous mutations
Finance
Astrea Bioseparations invests in infrastructure in UK and Singapore
The company has expanded its R&D facility in Cambridge, UK, and registered a branch office in Singapore
Finance
Avacta appoints Chief Scientific Officer of therapeutics division
Dr Alastair Smith, CEO of Avacta Group, commented: “We are delighted to have Fiona McLaughlin join us as Chief Scientific Officer of our therapeutics division
Finance
Avacta appoints Dr Mark Goldberg as Non-Executive Director
Goldberg currently serves on the boards of directors of ImmunoGen, Idera Pharmaceuticals, GlycoMimetics, Walden Biosciences, and Blueprint Medicines
Subscribe now